Phase III Study in Refractory Behcet's Disease

Exclusion Criteria

• •Patients not meeting the above specified criteria for immunomodulatory therapies are eligible for enrollment if they are intolerant to systemic immunomodulatory therapy as determined by the study investigator.
• •Subjects with infectious uveitis, uveitis due to other causes than Behçet's disease, or uveitis of unknown etiology.
• •Less severe (i.e. anterior) uveitis associated with Behçet's disease.
• •Ocular treatments
• •Treatment with intravitreal anti-VEGF agents administered to the study eye within 3 months prior to study screening.
• •Treatment with any injected or implantable corticosteroid releasing device (i.e., flucinolone acetonide implant, Retisert®) in the study eye within the last 3 years.
• •Intraocular surgery or laser photocoagulation in the study eye within the last 6 weeks prior to screening except for a diagnostic vitreous or aqueous tap with a small-gauge needle.
• •Systemic conditions or treatments
• •Treatment with any live or live-attenuated vaccine (including vaccine for varicella-zoster virus or measles) within 2 months prior to screening.
• •Any systemic biologic therapy (e.g. interferon, infliximab, daclizumab, etanercept, or adalimumab) given intravenously or subcutaneously within 3 months prior to screening and no prior treatment with AIN457.
• •Any prior treatment with systemic alkylating agents (cyclophosphamide, chlorambucil).